Non-emergency patients undergoing surgery under general anesthesia
Conditions
Interventions
Remimazolam is administered at the assigned rapid intravenous dose, and at the same time, the continuous administration rate is started and the continuous administration is continued for 10 minutes. A
Sponsors
Nakajima Yoshiki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged between 20 and 45 at the time of consent 2. Gender: No matter 3.Patients planning to insert i-gel in non-emergency (scheduled / temporary) surgery 4. ASA (American Society of Anesthesiologists) Grade I or II patients 5. Persons who have obtained consent for this research by signing the consent form
Exclusion criteria
Exclusion criteria: 1. Those who are expected to have difficulty intubation (trismus, Malampati Grade III IV, etc.) 2. Patients undergoing surgery requiring tracheal intubation 3. Those with symptoms of respiratory tract infection 4. Patients with a history of hypersensitivity to benzodiazepines or flumazenil 5. Severe obesity (BMI 35 and above) 6. Pregnant patients 7. Lactating women and puerperal women 8. Those who may be aspirated 9. Persons with a history of hypersensitivity to Remimazolam 10. Patients who are excluded from other investigators / shared doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Predictive effect site concentration of remimazolam (EC50) for successful i-gel insertion in 50% of patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Predictive effect site concentration of remi-mazolam (EC95) for successful i-gel insertion in 95% of patients Changes in blood pressure / heart rate and changes in EEG monitor at each point (before the start of general anesthesia, before and after i-gel insertion) | — |
Contacts
Public ContactHisako Nishimoto
Hamamatsu University Hospital
Outcome results
None listed